Luque Raul M, Park Seungjoon, Kineman Rhonda D
Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Mol Cell Endocrinol. 2008 May 14;286(1-2):155-68. doi: 10.1016/j.mce.2007.12.005. Epub 2007 Dec 14.
Somatostatin (SST) was first described over 30 years ago as a hypothalamic neuropeptide which inhibits GH release. Since that time a large body of literature has accumulated describing how endogenous SST mediates its effects on GH-axis function under normal conditions and in response to metabolic extremes. This review serves to summarize the key findings in this field with a focus on recent progress, much of which has been made possible by the availability of genetically engineered mouse models and SST receptor-specific agonists.
30多年前，生长抑素（SST）首次被描述为一种抑制生长激素释放的下丘脑神经肽。从那时起，大量文献积累起来，描述了内源性SST在正常条件下以及对极端代谢情况作出反应时如何介导其对生长激素轴功能的影响。这篇综述旨在总结该领域的关键发现，重点关注近期进展，其中许多进展得益于基因工程小鼠模型和SST受体特异性激动剂的可用性。
